Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Half-Life"" wg kryterium: Temat


Starter badań:

Tytuł:
Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.
Autorzy:
Boof ML; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Géhin M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Voors-Pette C; QPS Netherlands BV, Groningen, The Netherlands.
Hsin CH; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Sippel V; Department of Translational Biomarkers, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Strasser DS; Department of Translational Biomarkers, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Dingemanse J; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Pokaż więcej
Źródło:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Feb; Vol. 90 (2), pp. 588-599. Date of Electronic Publication: 2023 Nov 16.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Half-Life*
Adult ; Humans ; Male ; Female ; Dose-Response Relationship, Drug ; Area Under Curve ; Double-Blind Method ; Healthy Volunteers ; Administration, Oral
Czasopismo naukowe
Tytuł:
Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A.
Autorzy:
Abdelgawad HAH; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA; Department of Child Health, University of Arizona College of Medicine, Phoenix, AZ, USA. Electronic address: .
Foster R; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA.
Otto M; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA; Department of Child Health, University of Arizona College of Medicine, Phoenix, AZ, USA. Electronic address: .
Pokaż więcej
Źródło:
Blood reviews [Blood Rev] 2024 Mar; Vol. 64, pp. 101164. Date of Electronic Publication: 2023 Dec 23.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hemophilia A*/drug therapy
Hemostatics*/therapeutic use
Humans ; Factor VIII/therapeutic use ; Half-Life ; Quality of Life
Czasopismo naukowe
Tytuł:
The significance of very long half-life in the context of antiseizure medication withdrawal during long-term video-EEG monitoring.
Autorzy:
Hampel KG; Refractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, University Hospital La Fe, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain. Electronic address: .
Morata-Martínez C; Refractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, University Hospital La Fe, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain.
Garcés-Sánchez M; Refractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, University Hospital La Fe, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain.
Villanueva V; Refractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, University Hospital La Fe, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain.
Pokaż więcej
Źródło:
Seizure [Seizure] 2024 Feb; Vol. 115, pp. 111-112. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Letter
MeSH Terms:
Seizures*/drug therapy
Substance Withdrawal Syndrome*/diagnosis
Humans ; Half-Life ; Anticonvulsants/adverse effects ; Electroencephalography
Opinia redakcyjna
Tytuł:
Influence of antiseizure medication on long-term video-eeg in focal epilepsy: The significance of half-life.
Autorzy:
Panda PK; Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand 249203, India.
Sharawat IK; Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand 249203, India. Electronic address: .
Pokaż więcej
Źródło:
Seizure [Seizure] 2024 Feb; Vol. 115, pp. 109-110. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Letter
MeSH Terms:
Epilepsies, Partial*/diagnosis
Epilepsies, Partial*/drug therapy
Humans ; Half-Life ; Seizures/diagnosis ; Seizures/drug therapy ; Electroencephalography
Opinia redakcyjna
Tytuł:
Impact of antiseizure medication with a very long half-life on long term video-EEG monitoring in focal epilepsy.
Autorzy:
Hampel KG; Refractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, University Hospital La Fe, Avenida Fernando Abril Martorell 106, Valencia 46026, Spain. Electronic address: .
Morata-Martínez C; Refractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, University Hospital La Fe, Avenida Fernando Abril Martorell 106, Valencia 46026, Spain.
Garcés-Sánchez M; Refractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, University Hospital La Fe, Avenida Fernando Abril Martorell 106, Valencia 46026, Spain.
Villanueva V; Refractory Epilepsy Unit, Neurology Service, Member of ERN EPICARE, University Hospital La Fe, Avenida Fernando Abril Martorell 106, Valencia 46026, Spain.
Pokaż więcej
Źródło:
Seizure [Seizure] 2024 Feb; Vol. 115, pp. 100-108. Date of Electronic Publication: 2023 Dec 16.
Typ publikacji:
Journal Article
MeSH Terms:
Epilepsy*/drug therapy
Epilepsies, Partial*/diagnosis
Epilepsies, Partial*/drug therapy
Humans ; Anticonvulsants/therapeutic use ; Retrospective Studies ; Half-Life ; Seizures/diagnosis ; Seizures/drug therapy ; Electroencephalography
Czasopismo naukowe
Tytuł:
Functionalisation of brush polyethylene glycol polymers with specific lipids extends their elimination half-life through association with natural lipid trafficking pathways.
Autorzy:
Abdallah M; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Lin L; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Styles IK; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Mörsdorf A; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Grace JL; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Gracia G; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Nowell C; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia.
Quinn JF; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia; Department of Chemical and Biological Engineering, Faculty of Engineering, Monash University, Clayton, VIC, Australia.
Landersdorfer CB; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Whittaker MR; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia. Electronic address: .
Trevaskis NL; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia. Electronic address: .
Pokaż więcej
Źródło:
Acta biomaterialia [Acta Biomater] 2024 Jan 15; Vol. 174, pp. 191-205. Date of Electronic Publication: 2023 Dec 10.
Typ publikacji:
Journal Article
MeSH Terms:
Polyethylene Glycols*/pharmacology
Polymers*
Rats ; Animals ; Tissue Distribution ; Half-Life ; Peptides/pharmacology ; Lipoproteins, HDL ; Cholesterol ; Serum Albumin, Bovine/pharmacology
Czasopismo naukowe
Tytuł:
A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B.
Autorzy:
Koopman SF; Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Goedhart TMHJ; Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Bukkems LH; Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Mulders TM; Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Leebeek FWG; Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Fijnvandraat K; Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Amsterdam, The Netherlands.
Coppens M; Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.; Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, The Netherlands.
Mathias M; Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Collins PW; Arthur Bloom Haemophilia Centre, School of Medicine, Cardiff University Hospital, Cardiff, UK.
Tait RC; Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK.
Bagot CN; Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK.
Curry N; Oxford Haemophilia and Thrombosis Centre and Oxford NIHR BRC, Nuffield Orthopaedic Hospital, Oxford, UK.
Payne J; Department of Paediatric Haematology, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
Chowdary P; Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, UK.
Cnossen MH; Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Mathôt RAA; Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Pokaż więcej
Corporate Authors:
OPTI-CLOT study group and SYMPHONY consortium
Źródło:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Jan; Vol. 90 (1), pp. 220-231. Date of Electronic Publication: 2023 Sep 12.
Typ publikacji:
Journal Article
MeSH Terms:
Factor IX*/therapeutic use
Factor IX*/pharmacokinetics
Hemophilia B*/drug therapy
Child ; Humans ; Child, Preschool ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged ; Retrospective Studies ; Prospective Studies ; Recombinant Fusion Proteins/therapeutic use ; Recombinant Fusion Proteins/pharmacokinetics ; Half-Life
Czasopismo naukowe
Tytuł:
Half-life of serum anti-Müllerian hormone and changes after gonadectomy in adult female and male dogs with normal and abnormal gonads.
Autorzy:
Balogh O; Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, USA.
Szilágyi E; Department of Obstetrics and Food Animal Medicine Clinic, University of Veterinary Medicine Budapest, Hungary.
Balogh N; Praxislab Ltd., Budapest, Hungary.
Somogyi Z; Department of Pharmacology and Toxicology, University of Veterinary Medicine Budapest, Hungary.
Müller L; Department of Obstetrics and Food Animal Medicine Clinic, University of Veterinary Medicine Budapest, Hungary; ATRC Aurigon Ltd., Dunakeszi, Hungary. Electronic address: .
Pokaż więcej
Źródło:
Theriogenology [Theriogenology] 2024 Mar 15; Vol. 217, pp. 18-24. Date of Electronic Publication: 2024 Jan 06.
Typ publikacji:
Journal Article
MeSH Terms:
Testicular Neoplasms*/veterinary
Cryptorchidism*/veterinary
Humans ; Dogs ; Female ; Male ; Animals ; Anti-Mullerian Hormone ; Half-Life ; Gonads ; Castration/veterinary
Czasopismo naukowe
Tytuł:
Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria.
Autorzy:
Foss S; Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway.
Sakya SA; Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway.
Aguinagalde L; Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Lustig M; Section for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Shaughnessy J; Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Cruz AR; Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Scheepmaker L; Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Mathiesen L; Department of Public Health, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Ruso-Julve F; Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway.
Anthi AK; Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway.
Gjølberg TT; Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway.
Mester S; Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway.
Bern M; Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway.
Evers M; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
Bratlie DB; Infection Immunology, Norwegian Institute of Public Health, Oslo, Norway.
Michaelsen TE; Infection Immunology, Norwegian Institute of Public Health, Oslo, Norway.; Department of Chemical Pharmacy, School of Pharmacy, University of Oslo, Oslo, Norway.
Schlothauer T; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Munich, Germany.
Sok D; International AIDS Vaccine Initiative (IAVI), New York, NY, USA.
Bhattacharya J; Antibody Translational Research Program, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, India.
Leusen J; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
Valerius T; Section for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Ram S; Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Rooijakkers SHM; Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Sandlie I; Department of Biosciences, University of Oslo, Oslo, Norway.
Andersen JT; Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. .; Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Oslo, Norway. .; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2024 Mar 07; Vol. 15 (1), pp. 2007. Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:
Journal Article
MeSH Terms:
Receptors, Fc*
Neoplasms*/therapy
Neoplasms*/drug therapy
Mice ; Animals ; Humans ; Immunoglobulin G ; Half-Life ; Anti-Bacterial Agents/therapeutic use ; Gram-Negative Bacteria/metabolism ; Gram-Positive Bacteria/metabolism ; Mice, Transgenic ; Antibodies, Monoclonal ; Histocompatibility Antigens Class I/metabolism
Czasopismo naukowe
Tytuł:
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
Autorzy:
Matino D; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Germini F; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; IRCCS Humanitas Research Hospital, Milan, Italy.
Chan AKC; Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
Decker K; Hamilton Health Sciences, McMaster Children's Hospital, Hamilton, Ontario, Canada.
Iserman E; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Chelle P; School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.
Edginton AN; School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.
Oladoyinbo O; School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.
Trinari E; Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
Keepanasseril A; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Iorio A; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2024 Mar; Vol. 30 (2), pp. 345-354. Date of Electronic Publication: 2024 Feb 20.
Typ publikacji:
Journal Article
MeSH Terms:
Factor VIII*/therapeutic use
Hemophilia A*/drug therapy
Humans ; Half-Life ; Quality of Life ; Canada ; Hemorrhage/drug therapy ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery.
Autorzy:
Désage S; Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France.
Nougier C; Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France.
Meunier S; Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France.
Chamouard V; Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France.
Jousselme E; Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France.
Dargaud Y; Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France.; Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France.; UR4609 Hémostase et Thrombose, Faculté de médecine RTH Laënnec, Université Claude Bernard Lyon 1, Lyon, France.
Lienhart A; Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France.
Pokaż więcej
Źródło:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2024 Mar; Vol. 30 (2), pp. 538-544. Date of Electronic Publication: 2023 Dec 27.
Typ publikacji:
Journal Article
MeSH Terms:
Factor VIII*/therapeutic use
Hemophilia A*/drug therapy
Immunoglobulin Fc Fragments*
Adult ; Humans ; Retrospective Studies ; Recombinant Fusion Proteins/therapeutic use ; Recombinant Proteins/therapeutic use ; Half-Life
Czasopismo naukowe
Tytuł:
Pharmacokinetics of gamma-hydroxybutyric acid in 6-week-old swine (Sus scrofa domesticus) after intravenous and oral administration.
Autorzy:
Cuypers C; Department of Large Animal Surgery, Anaesthesia and Orthopaedics, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Devreese M; Department of Pathobiology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Van Uytfanghe K; Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Stove C; Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Schauvliege S; Department of Large Animal Surgery, Anaesthesia and Orthopaedics, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Pokaż więcej
Źródło:
Journal of veterinary pharmacology and therapeutics [J Vet Pharmacol Ther] 2024 Mar; Vol. 47 (2), pp. 95-106. Date of Electronic Publication: 2023 Nov 20.
Typ publikacji:
Journal Article
MeSH Terms:
Sodium Oxybate*/pharmacokinetics
Hydroxybutyrates*
Animals ; Swine ; Area Under Curve ; Administration, Oral ; Administration, Intravenous/veterinary ; Biological Availability ; Sus scrofa ; Half-Life
Czasopismo naukowe
Tytuł:
Pharmacokinetics of meloxicam in pre-ruminant calves after intravenous, oral, and subcutaneous administration.
Autorzy:
Jokela A; Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.; Research Centre for Animal Welfare, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
Nyrhilä A; Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.; Research Centre for Animal Welfare, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
Adam M; Research Centre for Animal Welfare, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.; Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.; Pharmacology Department, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef, Egypt.
Salla K; Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
Raekallio M; Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
Aho R; Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.; Research Centre for Animal Welfare, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
Norring M; Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.; Research Centre for Animal Welfare, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
Hokkanen AH; Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.; Research Centre for Animal Welfare, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
Pokaż więcej
Źródło:
Journal of veterinary pharmacology and therapeutics [J Vet Pharmacol Ther] 2024 Mar; Vol. 47 (2), pp. 143-149. Date of Electronic Publication: 2023 Oct 28.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-Inflammatory Agents, Non-Steroidal*/pharmacokinetics
Thiazines*/pharmacokinetics
Cattle ; Animals ; Horses ; Meloxicam/therapeutic use ; Thiazoles/pharmacokinetics ; Half-Life ; Area Under Curve ; Pain/veterinary ; Administration, Oral ; Ruminants
Czasopismo naukowe
Tytuł:
Pharmacokinetics of doxycycline hyclate in pigs with a new feed premix formulation.
Autorzy:
Zermeño-Acosta M; Departamento de Fisiología y Farmacología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, México City, Mexico.
Sumano H; Departamento de Fisiología y Farmacología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, México City, Mexico.
Villar JL; Departamento de Cirugía, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, México City, Mexico.
Bernad MJ; Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, México City, Mexico.
Gutiérrez L; Departamento de Fisiología y Farmacología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, México City, Mexico.
Pokaż więcej
Źródło:
Journal of veterinary pharmacology and therapeutics [J Vet Pharmacol Ther] 2024 Mar; Vol. 47 (2), pp. 107-113. Date of Electronic Publication: 2023 Nov 28.
Typ publikacji:
Randomized Controlled Trial, Veterinary; Journal Article
MeSH Terms:
Doxycycline*/pharmacokinetics
Anti-Bacterial Agents*/pharmacokinetics
Male ; Animals ; Swine ; Biological Availability ; Area Under Curve ; Half-Life
Czasopismo naukowe
Tytuł:
Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
Źródło:
European journal of haematology [Eur J Haematol] 2024 Mar; Vol. 112 (3), pp. 479. Date of Electronic Publication: 2023 Nov 20.
Typ publikacji:
Journal Article
MeSH Terms:
Hemophilia A*/drug therapy
Glycoproteins*
Humans ; Half-Life ; Factor VIII/therapeutic use ; Recombinant Proteins/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł:
An Albumin-Holliday Junction Biomolecular Modular Design for Programmable Multifunctionality and Prolonged Circulation.
Autorzy:
Dinesen A; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Andersen VL; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Elkhashab M; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Pilati D; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Bech P; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Fuchs E; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Samuelsen TR; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Winther A; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Cai Y; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Märcher A; Interdisciplinary Nanoscience Center (iNANO) and Department of Chemistry, Aarhus University, DK-8000 Aarhus C, Denmark.
Wall A; Department of Chemistry, University College London, London WC1H 0AJ, U.K.
Omer M; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Nielsen JS; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Chudasama V; Department of Chemistry, University College London, London WC1H 0AJ, U.K.
Baker JR; Department of Chemistry, University College London, London WC1H 0AJ, U.K.
Gothelf KV; Interdisciplinary Nanoscience Center (iNANO) and Department of Chemistry, Aarhus University, DK-8000 Aarhus C, Denmark.
Wengel J; Nucleic Acid Center, Department of Physics, Chemistry, and Pharmacy, University of Southern Denmark, DK-5230 Odense M, Denmark.
Kjems J; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Howard KA; Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
Pokaż więcej
Źródło:
Bioconjugate chemistry [Bioconjug Chem] 2024 Feb 21; Vol. 35 (2), pp. 214-222. Date of Electronic Publication: 2024 Jan 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
DNA, Cruciform*
Serum Albumin, Human*/metabolism
Mice ; Animals ; Infant, Newborn ; Humans ; Mice, Transgenic ; ErbB Receptors/metabolism ; Half-Life
Czasopismo naukowe
Tytuł:
Determinants of PFOA Serum Half-Life after End of Exposure: A Longitudinal Study on Highly Exposed Subjects in the Veneto Region.
Autorzy:
Batzella E; Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Rosato I; Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Pitter G; Screening Unit, Azienda Zero-Veneto Region, Padova, Italy.
Da Re F; Directorate of Prevention, Food Safety, and Veterinary Public Health-Veneto Region, Venice, Italy.
Russo F; Directorate of Prevention, Food Safety, and Veterinary Public Health-Veneto Region, Venice, Italy.
Canova C; Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Fletcher T; London School of Hygiene and Tropical Medicine, London, United Kingdom.
Pokaż więcej
Źródło:
Environmental health perspectives [Environ Health Perspect] 2024 Feb; Vol. 132 (2), pp. 27002. Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
Drinking Water*/chemistry
Water Pollutants, Chemical*/analysis
Alkanesulfonic Acids*
Fluorocarbons*
Environmental Pollutants*
Male ; Child ; Young Adult ; Humans ; Female ; Environmental Exposure/analysis ; Longitudinal Studies ; Half-Life ; Caprylates
Czasopismo naukowe
Tytuł:
PRKCSH contributes to TNFSF resistance by extending IGF1R half-life and activation in lung cancer.
Autorzy:
Shin GC; Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, 16419, Republic of Korea. .; Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea. .
Lee HM; Department of Applied Chemistry, Institute of Natural Science, Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University, Yongin, 446-701, Republic of Korea.; Department of Biomedical Science and Technology, Kyung Hee Medical Science Research Institute, Kyung Hee University, Seoul, 02453, Republic of Korea.
Kim N; Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Seo SU; Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea.
Kim KP; Department of Applied Chemistry, Institute of Natural Science, Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University, Yongin, 446-701, Republic of Korea.; Department of Biomedical Science and Technology, Kyung Hee Medical Science Research Institute, Kyung Hee University, Seoul, 02453, Republic of Korea.
Kim KH; Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, 16419, Republic of Korea. .
Pokaż więcej
Źródło:
Experimental & molecular medicine [Exp Mol Med] 2024 Feb; Vol. 56 (1), pp. 192-209. Date of Electronic Publication: 2024 Jan 10.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Animals ; Mice ; Humans ; Half-Life ; Cell Line, Tumor ; Mice, Inbred NOD ; Mice, SCID ; Tumor Necrosis Factors/metabolism ; Calcium-Binding Proteins ; Glucosidases/metabolism ; Receptor, IGF Type 1/metabolism
Czasopismo naukowe
Tytuł:
Effects of chitooligosaccharide on the in vitro antibacterial activity against avian Escherichia coli and the pharmacokinetics of florfenicol in healthy chickens.
Autorzy:
Zhang M; College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China.
Li ZE; College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China.
Duan MH; College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China.
Dai Y; College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China.
Jin YG; College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China.
Liu Y; College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China.
Zhang YN; College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China.
Li XP; College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China.
Yang F; College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China. Electronic address: .
Pokaż więcej
Źródło:
Poultry science [Poult Sci] 2024 Feb; Vol. 103 (2), pp. 103373. Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Randomized Controlled Trial, Veterinary; Journal Article
MeSH Terms:
Thiamphenicol*/*analogs & derivatives
Chickens*
Thiamphenicol*/pharmacology
Oligosaccharides*
Chitosan*
Animals ; Escherichia coli ; Anti-Bacterial Agents ; Half-Life
Czasopismo naukowe
Tytuł:
Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.
Autorzy:
Kaneda-Nakashima K; Laboratory of Radiation Biological Chemistry, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.; MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.; Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.
Shirakami Y; MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.; Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.
Kadonaga Y; MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.; Nuclear Medicine, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan.
Watabe T; MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.; Nuclear Medicine, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan.
Ooe K; MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.; Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.
Yin X; Nishina Center for Accelerator-Based Science Nuclear Chemistry Group, RIKEN, Wako 351-0198, Japan.
Haba H; Nishina Center for Accelerator-Based Science Nuclear Chemistry Group, RIKEN, Wako 351-0198, Japan.
Shirasaki K; Laboratory of Alpha-Ray Emitters, Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan.
Kikunaga H; Research Center for Electron Photon Science, Tohoku University, Sendai 982-0826, Japan.
Tsukada K; Research Group of Heavy Element Nuclear Science, Advanced Science Research Center, Japan Atomic Energy Agency, Naka-gun 319-1195, Japan.
Toyoshima A; MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.; Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.
Cardinale J; Nuclear Medicine Department, University Hospital Düsseldorf, 40225 Düsseldorf, Germany.
Giesel FL; Nuclear Medicine Department, University Hospital Düsseldorf, 40225 Düsseldorf, Germany.
Fukase K; MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.; Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.; Natural Product Chemistry, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 11; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms*/drug therapy
Radioisotopes*/therapeutic use
Prostate-Specific Antigen*
Humans ; Male ; Half-Life ; Nuclear Medicine
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies